Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

Euro Surveill. 2020 May;25(18):2000603. doi: 10.2807/1560-7917.ES.2020.25.18.2000603.

Abstract

Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.

Keywords: COVID-19; IgA; IgG; SARS-CoV-2; commercial; serology.

Publication types

  • Evaluation Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Automation, Laboratory
  • Betacoronavirus
  • COVID-19
  • COVID-19 Testing
  • Child
  • Child, Preschool
  • Clinical Laboratory Techniques / methods*
  • Clinical Laboratory Techniques / standards
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / epidemiology
  • Enzyme-Linked Immunosorbent Assay / methods*
  • Finland / epidemiology
  • Humans
  • Immunoglobulin A / blood*
  • Immunoglobulin G / blood*
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / epidemiology
  • Reagent Kits, Diagnostic / standards*
  • Reproducibility of Results
  • Retrospective Studies
  • SARS-CoV-2
  • Sensitivity and Specificity
  • Young Adult

Substances

  • Immunoglobulin A
  • Immunoglobulin G
  • Reagent Kits, Diagnostic